A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B

Author： Spackman D. Eldon   Veenstra David L.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.26, Iss.11, 2008-01, pp. : 937-949

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B

By Veenstra David L.  

PharmacoEconomics, Vol. 25, Iss. 11, 2007-01 ,pp. : 963-977

Adis International

Access to resources Recommend Favorite

Entecavir of benefit in HBeAg-positive Hep B

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 542, 2007-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Lamivudine for the Treatment of Chronic Hepatitis B

By Crowley S.J.  

PharmacoEconomics, Vol. 17, Iss. 5, 2000-05 ,pp. : 409-427

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis

By Wu Bin   Li Te   Chen Huafeng   Shen Jinfang  

Value in Health, Vol. 13, Iss. 5, 2010-08 ,pp. : 592-600

Blackwell Publishing

Access to resources Recommend Favorite

Evaluation of Hepatitis B Viraemia Levels in Patients with HBeAg-negative Chronic Hepatitis B Virus Infection

By Atay AE   Seven G   Yalcin K   Pasa S   Degertekin H  

The Journal of International Medical Research, Vol. 40, Iss. 5, 2012-09 ,pp. : 1891-1896

Field House Publishing

Access to resources Recommend Favorite